Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on These Healthcare Stocks: PROCEPT BioRobotics (PRCT), Sanuwave Health (SNWV)

Tipranks - Tue Mar 17, 9:10AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on PROCEPT BioRobotics (PRCTResearch Report), Sanuwave Health (SNWVResearch Report) and Scholar Rock Holding (SRRKResearch Report) with bullish sentiments.

Claim 70% Off TipRanks Premium

PROCEPT BioRobotics (PRCT)

William Blair analyst Brandon Vazquez maintained a Buy rating on PROCEPT BioRobotics today. The company’s shares closed last Monday at $27.76.

According to TipRanks.com, Vazquez ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -5.7% and a 27.9% success rate. Vazquez covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Irhythm Technologies, and Edwards Lifesciences. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for PROCEPT BioRobotics with a $35.22 average price target, implying a 29.8% upside from current levels. In a report issued on March 2, Piper Sandler also maintained a Buy rating on the stock with a $28.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Sanuwave Health (SNWV)

In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Sanuwave Health, with a price target of $55.00. The company’s shares closed last Monday at $21.65, close to its 52-week low of $18.50.

According to TipRanks.com, Byrnes has 0 stars on 0-5 stars ranking scale with an average return of -5.7% and a 33.8% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as TriSalus Life Sciences, BioLife Solutions, and Avita Medical. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sanuwave Health with a $54.00 average price target.

Scholar Rock Holding (SRRK)

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Scholar Rock Holding. The company’s shares closed last Monday at $40.55, close to its 52-week high of $46.98.

According to TipRanks.com, Ahmad is a 2-star analyst with an average return of 0.0% and a 50.7% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, KalVista Pharmaceuticals, and Apellis Pharmaceuticals. ;'>

Currently, the analyst consensus on Scholar Rock Holding is a Strong Buy with an average price target of $56.50, which is a 40.3% upside from current levels. In a report issued on March 5, TipRanks – Google also upgraded the stock to Buy with a $53.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.